

“Association of Anti-CCP Antibodies with Disease Activity in Rheumatoid Arthritis”

Dr. Md. Monwar Hossain¹, Dr. Abdur Razzaque², Dr. Md. Ahsan Habib³, Dr. Md. Moniruzzaman Asraf⁴, Dr. Md. Aminul Hasan⁵

¹Assistant Professor. Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh

²Assistant Professor. Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh

³Assistant Professor. Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh

⁴Assistant Professor. Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh

⁵Assistant Professor. Department of Medicine, Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh

Corresponding author: Dr. Md. Monwar Hossain

Abstract

Background: Rheumatoid arthritis (RA) is an autoimmune disease and it is characterized by the production of autoantibodies specific for the disease like rheumatoid factor, antibodies against cyclic citrullinated peptides (Anti-CCP), antinuclear autoantibodies (ANA) etc. We have very few specific data regarding these issues.

Aim of the study: The aim of this study was to describe the frequency of anti-CCP positivity in active rheumatoid arthritis.

Methods: This was an observational cross sectional study which was conducted in the Rheumatology Out Patient Department and Medicine Indoor, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh during the period from January 2009 to December 2010. In total 165 patients with RA attended the mentioned units with proper documents were finalized as the study population. A pre-designed semi-structured questioner was used in collecting patient data. All data were collected, processed, analyzed and disseminated by MS-Office and SPSS version 20 as per need.

Result: In this study, the DAS 28 score was significantly higher in anti-CCP positive patients than anti-CCP negative patients (6.3 ± 0.92 vs. 5.9 ± 0.8 , $p = 0.017$). The number of tender joint count and swollen joint count were significantly higher in the anti-CCP positive group than those in the anti-CCP negative group (31 ± 12 vs. 24 ± 12 , $p = 0.003$; 6 ± 5 vs. 3 ± 2 , $p = 0.002$ respectively). ESR (mean \pm SD) was 61.7 ± 31.4 in Anti-CCP positive group and 48.9 ± 19.6 in Anti-CCP negative group, which was significantly higher in the Anti-CCP positive group ($P = 0.032$). Anaemia was significantly higher in Anti-CCP positive group (55.3% vs. 33.3% , $p = 0.023$). Patient's global assessment of disease activity and physician's global assessment of disease activity were also higher in the Anti-CCP positive group than negative group, which was nearly significant (57.0 ± 15.4 vs. 52.7 ± 9.8 , $p = 0.054$; 51.0 ± 15.6 vs. 45.2 ± 12.5 , $p = 0.053$ respectively). On the other hand, there was no statistically significant difference in term of disease duration, VAS, HAQ, morning stiffness > 60 minutes, CRP, Haemoglobin, platelet count and joint deformity ($p > 0.05$). In comparison of disease activity indices level between Anti-CCP positive and negative patients with RA we observed DAS 28 was not associated with anti-CCP positivity ($P = 0.410$), HAQ score < 1 was significantly less in patients with anti-CCP negativity ($P = 0.02$), patient's global assessment and physician's global assessment score were much higher in the anti-CCP positive group and number of tender joint count was significantly higher in the former group.

Conclusion: Anti-CCP antibodies test should be continued for diagnosis of rheumatoid arthritis especially for the RF negative rheumatoid arthritis patients. Anti-CCP antibody test does not appear to be useful as a marker of disease activity in rheumatoid arthritis.

Key words: Anti-CCP antibody, DAS 28, Disease Activity, Rheumatoid arthritis.

Date of Submission: 16-02-2021

Date of Acceptance: 02-03-2021

I. Introduction

Rheumatoid arthritis (RA) is an autoimmune disease and it is characterized by the production of autoantibodies specific for the disease like rheumatoid factor, antibodies against cyclic citrullinated peptides (Anti-CCP), antinuclear autoantibodies (ANA) etc. We have very few specific data regarding these issues. Rheumatoid arthritis (RA) is the most common autoimmune disease affecting approximately 1% of the world's populations¹. Chronic inflammation of the involved joints results in progressive loss of function, which, together with the extra-articular manifestations and adverse events of therapy, may increase morbidity and mortality of patients with RA². The onset is most frequent during the fourth and fifth decades of life with 80% of all patients

developing the disease between the ages of 35-50 and women are affected approximately three times more often than men³. The overall prevalence of RA in Bangladesh is 0.7% in rural population and 0.4% in urban population⁴. Although the etiology and pathogenesis remain unclear, recent data suggest that RA generally results from acute and chronic inflammation in the synovium associated with a proliferative and destructive process in the joint. Affected areas may either heal without lasting structural defects, or be irreversibly damaged or destroyed if inflammation is severe and does not remit. Measures aimed at identifying early active disease and ameliorating inflammation are therefore essential and may be highly effective in modifying disease outcome. Assessment of disease activity in patients with RA is currently based upon the following factors: Patient and physician assessment of symptoms and functional status, evaluation of joint involvement and extra-articular manifestations, laboratory markers and radiographic studies⁴. Common indicators of disease activity in RA include the following measurements⁶: Swollen and tender joint counts, Pain, Patient and Physician's global assessments of disease activity, Erythrocyte sedimentation rate and C-reactive protein (ESR, CRP), Duration of morning stiffness, Fatigue, Measures of function (e.g. Health Assessment Questionnaire), Health status (e.g. Short Form 36). Because no single measure that is adequate has been identified to measure disease activity in RA⁷, disease indices has been developed which are measures that combine several outcomes within in a single score and that incorporate both subjective (i.e. joint count and patient's assessment of disease activity) and objective (i.e. acute phase reactants, radiographic imaging results) measurements⁸. Several composite indices are available to measure rheumatoid arthritis activity on a continuous scale. These include the Disease Activity Score (DAS), the DAS based on 28 joint counts (DAS 28), the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI). These indices are essentially based on some attributes of RA: joint counts, the patient's evaluation of RA activity and acute phase reactants⁹. The DAS 28 score is used extensively to evaluate disease activity in patients with rheumatoid arthritis. DAS 28 is based on counts of tender and swollen joints (28 joints), the patient's global assessment of disease activity and the erythrocyte sedimentation rate (ESR). The 28 joint counts is a reliable and valid measure for joint assessment. It is easier to perform than the 66/68 joint count and it addresses the joint that are critically involved¹⁰. The modified DAS that include 28 joint counts are able to discriminate between high and low disease activity. The modified DAS (DAS 28) is as valid as disease activity scores that include more comprehensive joint count¹¹. To assess the disease activity by composite indices (DAS 28, SDAI, CDAI) are time consuming and often not suitable to measure disease activity in out-patient setting and also based on subjective and objective measure. As subjective measure of disease activity (i.e. joint count, physician's global assessment of disease activity and patient's global assessment of disease activity) based on individual judgment and may be influenced by different factors such as knowledge, experience and practice. On the other hand objective measure (i.e. acute phase reactant- ESR, CRP) are commonly used to measure disease activity are not specific for RA and are influenced by several other variables. With the availability of new biological agents and the introduction of the quality improvement movement into rheumatology, the development of valid and feasible measures of disease activity in RA has become an active research⁸. It is now established that duration of active disease is associated with joint damage and disability¹², there is a critical need for disease activity measures that can be performed in busy out-patient setting. So to identify the potential serological markers of RA activity especially autoantibodies, can optimize treatment of RA particularly in the early phase of the disease, thereby avoiding its progression to erosive, destructive and disabling forms. Rheumatoid arthritis is associated with many auto-antibodies of diverse specificities, reflecting the humoral autoimmune aetiopathogenesis of RA. Rheumatoid factors (RF), the time honored serological maker has been around for more than 50 years. RF has a sensitivity of 70-80% in diagnosis of RA but specificity is poor as it found in several other conditions like other autoimmune disease, infections and 5-10% of healthy elderly individuals. However RF positivity is an independent predictor of erosive disease as shown in a cohort followed up for 5-12 years¹³ and the presence of RF is considered to be a determinant of disease severity and activity¹⁴. The shortcomings of the RF assay have provided impetus for identification of other serological assays for R.A. Citrullinated peptides (fillaggrin, keratin, vimentin etc.) are considered to be potential autoantigens driving the immune response in RA. Auto-antibodies against citrullinated antigen% have, been shown to be highly specific for RA. Anti-cyclic citrullinated peptide (Anti. CCP) antibodies, first described in 1998, were shown to be highly specific (95%) in the diagnosis of RA and slightly less sensitive than RF (60-80%)¹⁵. Serum concentration of antibodies against CCP (anti CCP) seems to be just as sensitive as and more specific than RF for diagnosing of RA and predicting its progression (Kristine 2007). In patient with undifferentiated arthritis, anti-CCP antibodies may predict those who are more likely to develop RA¹⁶. Several studies that have followed up cohorts of early RA patients for up to 6 yrs. have shown that anti CCP antibodies are an independent factor in predicting development of erosion¹⁷. There are number of reports from different studies observed that anti-CCP antibodies positivity has been found to be associated with greater disease activity in rheumatoid arthritis patients¹⁸. However, there are some studies where the authors failed to found association between anti-CCP antibodies positivity and disease activity in rheumatoid arthritis¹⁹. Although the presence of anti-CCP is accepted to be a reliable diagnostic and prognostic tool in RA²⁰, its association with disease activity

remains unclear. Moreover the usefulness of anti-CCP antibodies in the prediction of disease activity has not been studied in our population. So in the present study, association of anti-CCP antibodies with disease activity in rheumatoid arthritis patients in our population will be addressed.

II. Objectives

General Objective:

- To collect information regarding the frequency of anti-CCP positivity in active rheumatoid arthritis.

Specific Objective:

- To describe the titer of anti-CCP antibodies by severity in active rheumatoid arthritis.

III. Methodology & Materials

This was an observational cross sectional study which was conducted in the Rheumatology Out Patient Department and Medicine Indoor, Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh during the period from January 2009 to December 2010. In total 165 patients with RA attended the mentioned units with proper documents were finalized as the study population. A pre-designed semi-structured questioner was used in collecting patient data. Morning stiffness >1 hr for 6 weeks or more, arthritis of 3 or more joint areas for 6 weeks or more, arthritis of hand joints for 6 weeks or more, symmetrical arthritis for 6 weeks or more, rheumatoid nodules, serum rheumatoid factor and radiographic changes are considered as the indicators for defining RA. The presence of at least four indicators (Positive association) are considered for defining RA. According to the inclusion criteria patients fulfilled American College of Rheumatology (ACR) 1987 revised criteria for rheumatoid arthritis and patients of age of ≥ 18 to ≤ 70 years were included in this study. On the other hand, according to the exclusion criteria of this study, Patients having an overlap of RA with other rheumatic disease like systemic lupus erythematosus, systemic sclerosis etc. clinically, smokers, pregnant women, Known cases of diabetes mellitus, chronic renal failure, heart diseases and patients not providing consent were excluded from this study. The Rheumatoid Arthritis Disease Activity Score (DAS 28) was used to define disease activity in our population, where a DAS 28 score ≤ 2.6 is considered to reflect inactive disease and score > 5.1 indicate high active disease. Disease severity was also assessed using the visual analogue score (VAS). Severity was scored from 0 to 100 mm on three separate scales. The first and second visual analogue score were done by patient who report on the pain (0 mean no pain, 100 mean extreme pain) and the global assessment of RA activity respectively (0 mean no active disease, 100 mean highly active disease). Bengali Health assessment questioner (HAQ) is a questioner to patients whether he/she can perform his/her daily house hold activities e.g. holding something, dressing, cooking, bathing etc. and it was assessed by 0-3 points where 0 means no disability and 3 means extreme disability. All data were collected, processed, analyzed and disseminated by MS-Office and SPSS version 20 as per need.

IV. Result

In this study 2.56%, 17.31%, 25.64%, 30.13%, 21.79% and 8.33% participants were from 18-20, 21-30, 31-40, 41-50, 51-60 and 61-70 years' age groups respectively. The mean (\pm SD) age was 40.8 ± 11.6 years and the age range of the participants was 10 to 70 years. Male-female ratio of total participants was 1:5.1. So female were dominating in number. In total 95.76% participants of this study was married whereas 4.24% were unmarried. In only 17.58% participant family history of RA was found. Most of the participants (69%) was literate. Monthly family income of most of the participants (87%) was <10,000. According to the Anti-CCP test 80% participants were found as Anti-CCP positive whereas 20% were found as negative. There was no statistically significant difference in term of age ($p=0.052$), sex ($p=0.461$), marital status ($p= 0.575$), family history of RA ($p=0.357$), level of education ($p=0.448$), family income ($p=0.400$) between anti-CCP positive and negative groups. So all demographic characteristics were almost identically distributed between the study groups. Out of 165 patients, 80% were Anti-CCP positive and 73.3% patients were RF (Rheumatoid factors) positive. Among the 44 RF negative patients 52.3% patients were Anti-CCP positive. In this study we found, more than 82% of the Anti-CCP positive cases were RF positive as opposed to 36.4% of Anti-CCP negative cases ($P<0.001$). Comparison of disease and disease activity related variables between Anti-CCP positive and Anti-CCP negative groups are illustrated. The DAS 28 was significantly higher in anti-CCP positive patients than anti-CCP negative patients (6.3 ± 0.92 vs. 5.9 ± 0.8 , $p = 0.017$). The number of tender joint count and swollen joint count were significantly higher in the anti-CCP positive group than those in the anti-CCP negative group (31 ± 12 vs. 24 ± 12 , $p=0.003$; 6 ± 5 vs. 3 ± 2 , $p=0.002$ respectively). ESR (mean \pm SD) was 61.7 ± 31.4 in Anti-CCP positive group and 48.9 ± 19.6 in Anti-CCP negative group, which was significantly higher in the Anti-CCP positive group ($P=0.032$). Anaemia was significantly higher in Anti-CCP positive group (55.3% vs. 33.3%, $p=0.023$). Patient's global assessment of disease activity and physician's global assessment of disease activity were also higher in the Anti-CCP positive group than negative group, which was nearly significant (57.0 ± 15.4 vs. 52.7 ± 9.8 , $p=0.054$; 51.0 ± 15.6 vs. 45.2 ± 12.5 , $p= 0.053$ respectively). On the other hand, there was no

statistically significant difference in term of disease duration, VAS, HAQ, morning stiffness > 60 minutes, CRP, Haemoglobin, platelet count and joint deformity (p> 0.05).

As per the comparison of disease activity indices level between Anti-CCP positive and negative patients with RA we observed, DAS 28 was not found to be associated with anti-CCP positivity (P=0.410) HAQ score < 1 significantly less in patients with anti-CCP positivity than that in patients with anti-CCP negativity (P=0.02). VAS score for pain was almost identically similar between the groups (P>0.05). Patient’s global assessment and Physician’s global assessment score were much higher in the anti-CCP positive group. Number of tender joint count was significantly higher in the former group, though the swollen joint count was almost similar in both groups. ESR > 80 mm in 1st hour was much higher in the former group than that in the latter group (P < 0.05).

Table I: Demographic characteristics of participants (N=165)

Characteristics	n	%
Age in years		
18-20	4	2.56
21-30	27	17.31
31-40	40	25.64
41-50	47	30.13
51-60	34	21.79
61-70	13	8.33
Mean ± SD	40.8±11.6	
Range (Years)	18-70	
Sex		
Male	27	16.36
Female	138	83.64
Male-Female ratio	01:5.1	
Marital Status		
Married	158	95.76
Unmarried	7	4.24
Family history of RA		
Present	29	17.58
Absent	136	82.42
Level of education		
Illiterate	51	30.91
Literate	114	69.09
Family income (Tk./Month)		
<10,000	144	87.27
>10,000	21	12.73




Figure I: Distribution of the participants regarding Anti-CCP (n=165)

Table II: Comparison of demographic characteristics of RA patients between Anti-CCP positive and negative groups (N=165)

Characteristics	Anti-CCP				P value
	Positive (n=132)		Negative (n=33)		
	n	%	n	%	
Age in years					
18-20	2	1.52	2	6.06	0.052
21-30	25	18.94	2	6.06	
31-40	32	24.24	8	24.24	
41-50	36	27.27	11	33.33	
51-60	27	20.45	7	21.21	
61-70	10	7.58	3	9.09	
Mean ± SD	40.3±11.6		42.4±11.3		0.347

Sex					
Male	23	17.42	4	12.12	0.461
Female	109	82.58	29	87.88	
Marital Status					
Married	126	95.45	32	96.97	0.575
Unmarried	6	4.55	1	3.03	
Family history of RA					
Present	25	18.94	4	12.12	0.357
Absent	107	81.06	29	87.88	
Level of education					
Illiterate	39	29.55	12	36.36	0.448
Literate	93	70.45	21	63.64	
Family income (Tk./Month)					
<10,000	116	87.88	28	84.85	0.4
>10,000	16	12.12	5	15.15	

Table III: Distribution of Anti-CCP and RF positivity in RA patients (N=165)

RF	Anti-CCP				Total	
	Positive (n=132)		Negative (n=33)		(n=165)	
	n	%	n	%	n	%
Positive	109	66.06	12	7.27	121	73.33
Negative	23	13.94	21	12.73	44	26.67
Total	132	80.00	33	20.00	165	100.00

Table IV: Association of Anti-CCP antibodies with RF (N=165)

RF	Anti-CCP				P value
	Positive (n=132)		Negative (n=33)		
	n	%	n	%	
Positive	109	82.58	12	36.36	0.052
Negative	23	17.42	21	63.64	

Table V: Comparison of disease and disease activity related variables between Anti-CCP positive and negative patients with RA (N=165)

Parameters	Anti-CCP		P value
	Positive (n=132)	Negative (n=33)	
Disease duration (Month)	43.5±37.7	46.0±41.8	0.741
DAS 28 score	6.3±0.92	5.9±0.8	0.017
VAS score in mm	57.1±15.6	52.4±15.0	0.125
Patient's Global Assessment score (mm)	57.0±15.4	52.7±9.8	0.054
Physician's Global Assessment score (mm)	51.0±15.6	45.2±12.5	0.053
Tender Joint Count	31±12	24± 12	0.003
Swollen Joint Count	6±5	3±2	0.002
HAQ score	1.1±0.5	0.9±0.4	0.081
Morning stiffness ≥ 60 min	68.8%	93.8%	0.37
Anaemia	55.3%	33.3%	0.023
ESR (mm in 1st hour)	61.7±31.4	48.9±19.6	0.032
CRP (mg /L)	30.2±3.1	27.7±6.8	0.73
Haemoglobin (gm/dl)	11.3±5.8	11.3±5.2	0.962
Platelet	335±82	298±78	0.541
Joint deformity	11.4%	9.1%	0.701

Table VI: Comparison of disease activity indices level between Anti-CCP positive and negative patients with RA (N=165)

Parameters	Anti-CCP				P value
	Positive (n=132)		Negative (n=33)		
DAS 28 score					
3.2-5.1	18	13.6	4	12.1	0.41
>5.1	114	86.4	29	87.9	0.41
HAQ score					
0-1	75	56.8	25	75.8	0.02
1-2	52	39.4	7	21.2	0.03
2-3	5	3.8	1	3.0	0.41
VAS score for pain (mm)					
0-30	6	4.5	3	9.1	0.16
30-60	92	69.7	25	75.8	0.23
60-90	34	25.8	5	15.2	0.09
Patient's Global Assessment score (mm)					

0-30	13	9.8	1	3.0	0.1
30-60	81	61.4	30	90.9	0.00
60-90	38	28.8	2	6.1	0.00
Physician's Global Assessment score (mm)					
0-30	19	14.4	6	18.2	0.24
30-60	89	67.4	26	78.8	0.13
60-90	24	18.2	1	3.0	0.02
Tender Joint Count					
0-10	12	9.1	8	24.2	0.05
10-20	44	33.3	10	30.3	0.01
>20	76	57.6	15	45.5	0.01
Swollen Joint Count					
0-10	120	90.9	32	97.0	0.05
10-20	8	6.1	1	3.0	0.11
>20	4	3.0	0	0.0	0.2
ESR (mm in 1st hour)					
0-20	10	7.6	2	6.1	0.38
20-40	35	26.5	11	33.3	0.22
40-60	28	21.2	14	42.4	0.01
60-80	24	18.2	4	12.1	0.20
>80	35	26.5	2	6.1	0.01
CRP (mg /L)					
0-5	27	20.5	5	15.2	0.25
5-10	25	18.9	12	36.4	0.02
10-15	13	9.8	0	0.0	0.03
15-20	9	6.8	5	15.2	0.06
>20	58	43.9	11	33.3	0.13

V. Discussion

The aim of this study was to describe the frequency of anti-CCP positivity in active rheumatoid arthritis. This cross-sectional study observed Frequency of anti-CCP antibodies positivity in active rheumatoid arthritis is similar to previous study²¹ and mean titer of anti-CCP antibodies did not differ significantly with differing levels of severity in rheumatoid arthritis. Thus anti-CCP antibodies test should be continued as a diagnostic test and may not be used as a marker of severity in active rheumatoid arthritis. In this study we observed, 80% patients were positive for anti-CCP antibody which compares well with the findings of Sockalingam et al.²² in Malaysian rheumatoid arthritis patients (80.4%). Our study included only active RA patients, while other studies compared wider cohort of patients, such as healthy control, palindromic rheumatism, undifferentiated arthritis and other connective tissue diseases²³. Anti-CCP antibodies although not yet part of the diagnostic criteria for RA, exhibit the highest specificity and a very high sensitivity for the disease.²⁴ They are also considered to have a prognostic value in predicting the development of RA in patients with undifferentiated arthritis and palindromic rheumatism.¹ Over half (52.3%) of RF negative RA patients were anti-CCP positive in our study. This results is consistent with the results of studies where anti-CCP positivity in RF negative patients were found to be between 20% and 43%²¹, which is an important point concerning the diagnostic value of anti-CCP. In the report published by Haq et al.⁴ the prevalence of RA in our country is high (0.7% in rural population and 0.4% in urban population). As the frequency of anti-CCP antibodies positivity in RA patients is high, anti-CCP antibodies test may serve as a better diagnostic marker for RA, if the test could be made available at an affordable cost. In the present study, we observed DAS-28, tender joint count, swollen joint count, patient's global assessment of disease activity, physician's global assessment of disease activity, ESR and RF positivity to be associated with anti-CCP positivity but no significant association of anti-CCP was found with duration of disease, morning stiffness, VAS, HAQ, CRP, haemoglobin, platelet count and joint deformity which was similar with several other studies. The value of anti-CCP antibodies for predicting the outcome of RA, clinical signs of disease activity and the severity of radiographic joint damage have been investigated recently. In addition to the predictive value of anti-CCP antibodies concerning radiological damage,²⁵ showed that anti-CCP is a good predictor of disease activity. Anti-CCP was found even better than RF in predicting disease activity after 3 years since the diagnosis of recent onset RA. Bas et al.²⁶ showed an association of RF and anti-CCP antibodies with clinical signs of disease activity. Onder²⁷ also observed that anti-CCP positivity was associated with higher scores of DAS-28 longer duration of morning stiffness, RF positivity, while it was not associated with disease duration, VAS, HAQ, ESR, CRP and haemoglobin. In this study, although the mean value of DAS-28 was observed to be significantly higher in patients with positive anti-CCP. But as DAS 28 was categorized into different levels of disease activity, these levels were not found to be associated with anti-CCP positivity. Low HAQ score (< 1) was significantly less in patients with anti-CCP positivity than that in patients with anti-CCP negativity but moderate HAQ score (1-2) was significantly higher in anti-CCP positive patients. This score may be attributed to subjective bias leading to over or underestimates. Patient's global assessment and

physician's global assessment scores were much higher in the anti-CCP positive group. However, these two indices may vary from individual to individual as they depend on knowledge, experience and level of education. Number of tender joint count was significantly higher in the former group, though the swollen joint count was almost similar in both groups. This variation between tender and swollen joint count might be due to the influence of NSAIDs and/or steroids. Though ESR > 80 mm in 1st hour was much higher in the former group than that in the latter group but other different levels of ESR were almost identical. Thus, the findings of the present study signify that anti-CCP antibody positivity was associated with disease severity. In our study, we found anti-CCP antibodies titer significantly correlated with DAS 28, patient's global assessment, physician's global assessment, VAS, HAQ, ESR and RF but no significant correlation with morning stiffness, tender joint count, swollen joint count, haemoglobin and CRP. With regards to anti-CCP titers, recent studies have showed that higher serum levels of anti-CCP correlate with higher DAS-28, enhanced inflammatory indices and more severe radiological pictures.¹⁸ Rezaei et al. observed that anti-CCP antibody titers were strongly positively correlated with titer of RF, ESR, DAS score but was not correlated with physician's global assessment, presence of radiographic erosions, disease duration and CRP. These findings are in agreement with findings of the present study. But as we arbitrarily divided the anti-CCP antibody titer level into three categories, the disease activity indices were not found to be associated with anti-CCP antibody titer, except low HAQ score and higher CRP. Though most of the disease activity related variables demonstrated significant correlation with anti-CCP antibodies titer when they were compared between the groups as quantitative variables. But as the same variables were compared among anti-CCP positive patients with three different antibody titer level, they no longer emerged as significant indicating that level of anti-CCP antibody titer is independent of disease severity. The present study revealed significant correlation, between anti-CCP titer and RF levels. Serdaroglu et al.²⁸ observed a small but significant correlation between RF and anti-CCP antibody, which was similar to our study. It is well-known that RF positivity is associated with more aggressive and erosive disease.³ All these findings suggest that anti-CCP antibodies may be a potential prognostic indicator. In our logistic regression analysis, we observed that RF positivity was associated with almost 8 times greater chance of being anti-CCP positive. Onder and associates²⁷, in a logistic regression analysis of multiple parameters, observed that higher DAS-28 scores and RF positivity carried 2 times and 9.89 times greater risk of being anti-CCP positive respectively. Papadopoulos et al.²⁹ in their study also found RF positivity, compared to RF negativity, conveyed a 17 times greater risk of being anti-CCP positive. So RF positivity was the strongest independent determinant of anti-CCP positivity. Like any other scientific studies, there were some limitations in the present study. Patients were recruited from one center and this was carried out over short period of time. In this study, we could not evaluate the effect of drugs therapy on disease activity and severity, though treatment resulted in significant decrease in disease activity scores. Strength of the current study includes an extensive training on data collection, midterm meeting with guide and co-guide was held for proper supervision and to maintain standard quality for laboratory investigations. From the present study it is suggested that though anti-CCP antibodies occur more frequently than RF in RA patients, its serum level does not correlate well with disease severity.

VI. Conclusion And Recommendations

Anti-CCP antibodies test should be continued for diagnosis of rheumatoid arthritis especially for the RF negative rheumatoid arthritis patients. Anti-CCP antibody test does not appear to be useful as a marker of disease activity in rheumatoid arthritis. But this was a single centered study with a small sized sample. So the findings of this study may not reflect the exact scenario of the whole country. For getting more specific findings we would like to recommend for conducting more studies regarding the same issue.

References

- [1]. Lee, W., Weisman, M.L., 2006. The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/environment/immunity interactions. *J Rheumatol*, 33, 1216-1217.
- [2]. Turesson, C., O'Fallon, M.W., Crowson, C.S., Gabriel, S.E., Matteson, E.L., 2002. Occurrence of extra-articular disease manifestation is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. *J Rheumatol*, 29, 62-67.
- [3]. Lipsky, P.E., 2008. Rheumatoid arthritis. *Harrison's Principles of Internal Medicine*, 17th edition, vol- 2, McGraw Hill, New York, 2083-2092.
- [4]. Haq, S.A., Darmawan, J., Islam, M.N., Uddin, M.Z., Das, B.B., Rahman, F., et al. 2005. Prevalence of rheumatic disease and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study. *J. Rheumatol*, 32, 348-353.
- [5]. Edward, D., Peter, H., Maini, R.N., et al., 2009. General principles of management of rheumatoid arthritis. *Up To Date*, June 19.
- [6]. Aletaha, D., 2006. Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? *Arthritis Res Ther*, 8(1),102.
- [7]. Van der Heijde, D.M., van't Hof, M.A., van Riel, P.L., et al. 1992. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. *Ann Rheum Diseases*, 51,177-81.
- [8]. Ringold, S., Singer, N.G., 2008. Measures of disease activity in rheumatoid arthritis: A clinician's guide. *Current Rheumatology Reviews*, 4, 259-265.

- [9]. Aletaha, D., Ward, M.M., Machold, K.P., Nell, V.P.K., Stamm, T., Smolen, J.S., 2005. Remission and active disease in Rheumatoid arthritis: Defining criteria for disease activity states. *Arthritis Rheum*, 52, 2625-2636.
- [10]. Smolen, J.S., Ferdinand, C., Breedveld, Eberl G., Jones, I., Leeming, M., Wylie, G.L., et al. 1995. Validity and reliability of the twenty-eight joint count for the assessment of rheumatoid arthritis activity. *Arthritis and Rheumatism*, 38, 38-43.
- [11]. Prevo, M.L.L., van't Hof, M.A., Juper, H.H., van Leeuwen, M.A., van de Patte, L.B.A., van Riel, P.L.C.M., 1995. Modified disease activity scores that include twenty-eight joint counts. *Arthritis Rheum*, 38, 44-48.
- [12]. Machold, K.P., Stamm, T.A., Nell, V.P. et al. 2007. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. *Rheumatology (Oxford)*, 46, 342-9.
- [13]. Sherre, Y.S., Bloch, D.A., Mitchell, D.M., Young, D.M., Fries, J.F., 1986. The development of disability in rheumatoid arthritis. *Arthritis Rheum*, 29, 494-500.
- [14]. O'Quinn, P. R. ; Knabe, D. A. ; Gregg, E. J. ; Lusas, E. W., 1997. Nutritional value for swine of soybean meal produced by isopropyl alcohol extraction. *J. Anim. Sci.*, 75 (3):714-719.
- [15]. Schellekens, G.A., de Jong, B.A.W., van den Hoogen, F.H.J., van de Putte, L.B.A., 1998. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. *J Clin Invest*, 101, 273-81.
- [16]. Marshall, S.E., 2010. Immunological factors in disease. *Davidson's Principles and Practice of Medicine*, 21st ed. Churchill Livingstone, Elsevier 81-85.
- [17]. Meyer, O., Labarre, C., Dougados, M., Goupille, Ph., Cantagrel, A., Dubois, A., et al. 2003. Anti citrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. *Ann Rheum Dis*, 62, 120-126.
- [18]. Del, Val, Amo, N., Bosch, R., Fito, Manteca, C., Gutierrez, Polo, R., Loza, Cortina, E., 2006. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: Relation with disease aggressiveness. *Clinical and experimental rheumatology*, 24, 281-286.
- [19]. Nell, V.P., Machold, K.P., Stamm, T.A., et al. 2005. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. *Ann Rheum Dis*, 64, 1731-1736.
- [20]. Zendman, A.J.W., van Venrooij, W.J., Pruijn, G.J.M., 2005. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. *Rheumatology* 1-6.
- [21]. Schellekens, G.A., Visser, H., De Jong, B.A.W., et al. 2000. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum*, 43, 155-63.
- [22]. Sockalingam, S., Khuan, C.S., Sthaneshwar, P., 2009. Prevalence of anti-cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity. *International Journal of Rheumatic disease*, 12, 211-215.
- [23]. Dubucquoi, S., Solau-Gervais, E., Lefranc, D., et al. 2004. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. *Ann Rheum Diseases*, 63, 415-419.
- [24]. Avouac, J., Gossec, L., Dougados, M., 2006. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. *Ann Rheum Diseases*, 65, 845-851.
- [25]. Kastbom, A., Strandberg, G., Lindroos, A., Skogh, T., 2004. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). *Ann Rheum Diseases*, 63, 1085-9.
- [26]. Bas, S., Genevay, S., Meyer, O., (Liabay, 2001. Anti cycle. citrullin00`11 of peptide antibodies, RA rheumatoid factors in the diagnosis and progn`". *rheumatoid arthritis. Rheumatology*, 42, 677-680.
- [27]. Onder, B., Kurtaran, A., Kimyon, S., Selcuk, B., Akyuz, M., 2009. Association of anti-CCP positivity with serum ferritin and DAS-28. *Rheumatol Int*. DOI 10.1007/s00296-009-0941-4.
- [28]. Serdaroglu, M., Cakirby, H., Deger, O., Cengiz, S., Kul Sibel., 2008. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. *Rheumatol Int*, 28, 965-970.
- [29]. Papadopoulos, N.G., Tsiaousis, G.Z., Galanopoulon, V.K., et al. 2008. Does the presence of anti-CCP antibodies and their serum level influence the severity and activity in rheumatoid arthritis patients? *Clini Rev Allerg Immunol*, 34, 11-15.

Dr. Md. Monwar Hossain, et. al. “Association of Anti-CCP Antibodies with Disease Activity in Rheumatoid Arthritis.” *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 20(02), 2021, pp. 22-29.